Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05788185
Other study ID # RV003
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date March 22, 2023
Est. completion date September 21, 2023

Study information

Verified date October 2023
Source RVAC Medicines (US), Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults. The study will be conducted at one site in Singapore.


Description:

A total of 48 healthy men and non-pregnant women aged 21 years and older will be stratified by prior vaccination. Twenty-four subjects who have received a 3 dose primary vaccination series, with or without 1 booster dose, of an approved inactivated virus vaccine (BBIBP-CorV or CoronaVac) will be randomized at a 1:1:1 ratio to receive RVM V001 (30 µg) only, RVM V002 (30 µg) only, or RVM-V001 (15 µg) + RVM V002 (15ug). An additional 24 subjects who have received 3 doses (primary vaccination series and 1 booster dose) of an mRNA vaccine (BNT162b2) will be randomized at 1:1:1 ratio to receive RVM-V001 (30 µg) only, RVM V002 (30 µg) only, or RVM-V001 (15 µg ) + RVM V002 (15 µg ). The last dose of the prior vaccination should have been administered at least 6 months prior to enrolment in this study. For administration of RVM V001 only or RVM V002 only, subjects will receive a single dose of RVM-V001 or RMV-V002 vaccine on Day 1 via intramuscular (IM) injection into deltoid muscle, preferably of the non-dominant arm. For the RVM V001 + RVM V002 administration, subjects will receive a single dose of RVM-V001 in the left arm deltoid muscle and then followed immediately with a single dose of RVM-V002 in the right arm deltoid muscle.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date September 21, 2023
Est. primary completion date September 21, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Male and female healthy volunteers. - Aged 21 years and older on Day 1 - Judged by the investigator to be healthy based on medical history, physical examination, and vital signs evaluation at Screening visit. - Able to provide informed consent form. - Able and willing to comply with all study procedures over follow-up period of approximately 6 months. - Have documented completion of a 2-dose primary vaccination series and 1 booster vaccination with BNT162b2 OR a 3-dose primary vaccination series, with or without 1 booster dose, with an approved inactivated virus vaccine (BBIBP-CorV or CoronaVac). The last dose in all cases should have been administered at least 6 months prior to enrolment in this study. - For female subjects with childbearing potential: must agree to avoid pregnancy from 21 days prior to Day 1 until at least 90 days after the last study vaccination. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Exclusion Criteria: - Received any COVID-19 vaccine other than BNT162b2, BBIBP-CorV, or CoronaVac. - Received more than 3 doses of BNT162b2 or more than 4 doses of BBIBP-CorV or CoronaVac. - Women who are pregnant or breastfeeding or intending to become pregnant; mend who will father children within the projected duration of the trial. - Positive serology test results for hepatitis C virus antibody, human immunodeficiency virus antibody, or hepatitis B viral surface antigen at Screening. - Is currently participating in or has participated in a study with an investigational product within 30 days preceding Day 1. - History of severe allergic reactions (eg, acute anaphylaxis, urticaria, skin eczema, dyspnoea, angioneurotic oedema) or other significant adverse reactions to COVID19 vaccines; allergy to known composition of RVM-001 and RVM-002. - History of coagulation dysfunction (eg, coagulation factor deficiency, coagulation disease). - Vaccinated with live attenuated vaccine within 1 month, or any other vaccine within 14 days, of Day 1 vaccination. - Received systemic immunosuppressants within 4 months prior to vaccination or an anticipated need for immunosuppressants at any time during the study. Topical or inhaled treatment is allowed if not used within 14 days prior to Day 1 vaccination. - Received blood products within 3 months prior to Day 1 vaccination. - History of alcohol or drug abuse within 3 years prior to Day 1 vaccination. - Fever (temperature > 37.5°C), dry cough, fatigue, nasal obstruction, runny nose, sore throat, myalgia, diarrhoea, shortness of breath, or dyspnoea on the day of vaccination. - Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled, could interfere with the evaluation of the study vaccine, or interfere with interpretation of the study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).

Study Design


Intervention

Biological:
RVM-V001 30 µg
For BNT162b2 subjects
RVM-V002 30 µg
For BNT162b2 subjects
RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
For BNT162b2 subjects
RVM-V001 30 µg
For BBIBP-CorV or CoronaVac subjects
RVM-V002 30 µg
For BBIBP-CorV or CoronaVac subjects
RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
For BBIBP-CorV or CoronaVac subjects

Locations

Country Name City State
Singapore P.H. Feng Research Centre, NCID,TTSH Singapore

Sponsors (1)

Lead Sponsor Collaborator
RVAC Medicines (US), Inc.

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety in terms of solicited adverse events Number of subjects with solicited adverse events Day 1 to Day 7 inclusive
Primary Safety in terms of solicited systemic adverse events Number of subjects with solicited systemic adverse events Day 1 to Day 7 inclusive
Primary Safety in terms of unsolicited adverse events Number of subjects with unsolicited adverse events Day 1 to Day 28 inclusive
Primary Safety in terms of SAEs, SUSARs, MAAEs and AESIs Number of subjects with SAEs, SUSARs, MAAEs and AESIs Day 1 to Day 180 post dose
Primary Safety in terms of laboratory-based AEs Changes in safety laboratory parameters from baseline by the Food and Drug Administration (FDA) toxicity grading scale. Day 1 to Day 180 post dose
Secondary Immunogenicity in terms of Nab GMT of neutralizing antibody (pseudoviral neutralization assay) against Wuhan strain and BA.1 subvariant Days 1,8,15,29 and 180
Secondary GMT of neutralizing antibody (pseudoviral neutralization assay) against Variants of Immunogenicity in terms of Nab GMT of neutralizing antibody (pseudoviral neutralization assay) against Variants of concerns of SARS-CoV-2 Days 1,8,15,29 and 180
Secondary Immunogenicity in terms of Humoral immune response by ELISA GMT of serum binding antibodies (IgG) by ELISA Days 1,8,15,29 and 180
Secondary Seroresponse rate for neutralizing antibody SRR percentage of subjects with =4-fold increase of antibody titer over baseline Days 8,15,29 and 180
Secondary Seroresponse rate for binding antibodies (IgG) by ELISA SRR percentage of subjects with =4-fold increase of antibody titer over baseline Days 8,15,29 and 180
Secondary Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Antibody Days 8,15,29 and 180
Secondary Geometric Mean Fold Rise (GMFR) of binding antibodies (IgG) by ELISA Days 8,15,29 and 180
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure